Back

State of the Art - PCSK9 in inhibitors therapy in clinical therapy

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: PCSK9 inhibitors: from cells to patients Risk Factors and Prevention ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Stephen Nicholls

Monash University, Melbourne (Australia)

4 More presentations in this session

Presentation thumbnail
The effect of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors on endothelial progenitor cells
Doctor O. Itzhaki Ben Zadok (Petah Tikva, IL)
Abstract
Presentation thumbnail
The effect of monoclonal antibodies against PCSK9 on circulating CD34+ progenitor cells interactions with platelets in patients with familial hypercholesterolemia.
Mrs A. Tsouka (Ioannina, GR)
Abstract Slides Video
Presentation thumbnail
Treatment of Hypercholesterolaemia with PCSK9 Inhibitors in Denmark. Assessment of real-life data; Extent and Efficacy after the first years of clinical use
Doctor S. Mulverstedt (Copenhagen, DK)
Abstract
Presentation thumbnail
Positioning PCSK9 inhibitors therapy in clinical practice.
Professor K. Ray (London, GB)
Slides Video

Access the full session

Session thumbnail
PCSK9 inhibitors: from cells to patients

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Presentation
Making personalised prevention everyone's business
thumbnail
Congress Presentation
Cardiovascular prevention in older adults
thumbnail
Congress Presentation
State-of-the-art lecture on closing the evidence-to-practice gap in cardiovascular pharmacotherapy: where are we still failing?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources